Skip Nav Destination
Issues
15 August 2019
-
Cover Image
Cover Image
The cover shows a section of the bone marrow biopsy from a patient with primary myelofibrosis. Reticulin staining shows diffusely increased bone marrow fibrosis, a hallmark of the disease pathology. For details, see the article by Gangat and colleagues on page 4898 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Regulatory Science and Policy
Review
Clinical Trials: Targeted Therapy
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda; Antoine Italiano; Cinta Hierro; Alain Mita; Andres Cervantes; Nancy Chan; Mark Awad; Emiliano Calvo; Victor Moreno; Ramaswamy Govindan; Alexander Spira; Martha Gonzalez; Bob Zhong; Ademi Santiago-Walker; Italo Poggesi; Trilok Parekh; Hong Xie; Jeffrey Infante; Josep Tabernero
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Naseema Gangat; Christian Marinaccio; Ronan Swords; Justin M. Watts; Sandeep Gurbuxani; Alfred Rademaker; Angela J. Fought; Olga Frankfurt; Jessica K. Altman; Qiang Jeremy Wen; Noushin Farnoud; Christopher A. Famulare; Akshar Patel; Roberto Tapia; Rangit R. Vallapureddy; Stephanie Barath; Amy Graf; Amy Handlogten; Darci Zblewski; Mrinal M. Patnaik; Aref Al-kali; Yvonne Trang Dinh; Kristen Englund Prahl; Shradha Patel; Juan Carlos Nobrega; Dalissa Tejera; Amber Thomassen; Juehua Gao; Peng Ji; Raajit K. Rampal; Francis J. Giles; Ayalew Tefferi; Brady Stein; John D. Crispino
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results
Matthew J. Wieduwilt; Nela Pawlowska; Scott Thomas; Rebecca Olin; Aaron C. Logan; Lloyd E. Damon; Thomas Martin; McNancy Kang; Peter H. Sayre; Wanda Boyer; Karin M.L. Gaensler; Kirsten Anderson; Pamela N. Munster; Charalambos Andreadis
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
Hui K. Gan; Michael Millward; Ye Hua; Chuan Qi; Yang Sai; Weiguo Su; Jian Wang; Lilin Zhang; Melanie M. Frigault; Shethah Morgan; Liu Yang; Jason D. Lickliter
Clinical Trials: Immunotherapy
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Margaret E. Gatti-Mays; Julius Strauss; Renee N. Donahue; Claudia Palena; Jaydira Del Rivero; Jason M. Redman; Ravi A. Madan; Jennifer L. Marté; Lisa M. Cordes; Elizabeth Lamping; Alanvin Orpia; Andrea Burmeister; Eva Wagner; Cesar Pico Navarro; Christopher R. Heery; Jeffrey Schlom; James L. Gulley
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Kevin C. Conlon; E. Lake Potter; Stefania Pittaluga; Chyi-Chia Richard Lee; Milos D. Miljkovic; Thomas A. Fleisher; Sigrid Dubois; Bonita R. Bryant; Michael Petrus; Liyanage P. Perera; Jennifer Hsu; William D. Figg; Cody J. Peer; Joanna H. Shih; Jason L. Yovandich; Stephen P. Creekmore; Mario Roederer; Thomas A. Waldmann
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Elizabeth L. McMichael; Brooke Benner; Lakhvir S. Atwal; Nicholas B. Courtney; Xiaokui Mo; Melanie E. Davis; Amanda R. Campbell; Megan C. Duggan; Kallan Williams; Kyle Martin; Kala Levine; Gonzalo N. Olaverria Salavaggione; Tiffany Noel; Akaansha Ganju; Sarvani Uppati; Bonnie Paul; Thomas Olencki; Theodoros N. Teknos; Panos Savvides; Susheela Tridandapani; John C. Byrd; Michael A. Caligiuri; Stephen V. Liu; William E. Carson, III
Precision Medicine and Imaging
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Vincent P. Groot; Stacy Mosier; Ammar A. Javed; Jonathan A. Teinor; Georgios Gemenetzis; Ding Ding; Lisa M. Haley; Jun Yu; Richard A. Burkhart; Alina Hasanain; Marija Debeljak; Hirohiko Kamiyama; Amol Narang; Daniel A. Laheru; Lei Zheng; Ming-Tseh Lin; Christopher D. Gocke; Elliot K. Fishman; Ralph H. Hruban; Michael G. Goggins; I. Quintus Molenaar; John L. Cameron; Matthew J. Weiss; Victor E. Velculescu; Jin He; Christopher L. Wolfgang; James R. Eshleman
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Author Choice
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao; Ding Ma; Shen Zhao; Chen Suo; Jinxiu Shi; Meng-Zhu Xue; Miao Ruan; Hai Wang; Jingjing Zhao; Qin Li; Peng Wang; Leming Shi; Wen-Tao Yang; Wei Huang; Xin Hu; Ke-Da Yu; Shenglin Huang; François Bertucci; Yi-Zhou Jiang; Zhi-Ming Shao; on behalf of AME Breast Cancer Collaborative Group
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Wenfeng Fang; Yuxiang Ma; Jiani C. Yin; Shaodong Hong; Huaqiang Zhou; Ao Wang; Fufeng Wang; Hua Bao; Xue Wu; Yunpeng Yang; Yan Huang; Hongyun Zhao; Yang W. Shao; Li Zhang
Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging
Stephen R. Bowen; Daniel S. Hippe; W. Art Chaovalitwongse; Chunyan Duan; Phawis Thammasorn; Xiao Liu; Robert S. Miyaoka; Hubert J. Vesselle; Paul E. Kinahan; Ramesh Rengan; Jing Zeng
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Katherine Tarlock; Todd A. Alonzo; Yi-Cheng Wang; Robert B. Gerbing; Rhonda Ries; Michael R. Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C. Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S. Gamis; Soheil Meshinchi; Jessica A. Pollard
Translational Cancer Mechanisms and Therapy
Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Zhe Su; Zhijie Wang; Xiaohui Ni; Jianchun Duan; Yan Gao; Minglei Zhuo; Ruoyan Li; Jun Zhao; Qi Ma; Hua Bai; Hengyu Chen; Shuhang Wang; Xixi Chen; Tongtong An; Yuyan Wang; Yanhua Tian; Jiangyong Yu; Di Wang; Xiaoliang Sunney Xie; Fan Bai; Jie Wang
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer
Siwen Hu-Lieskovan; Aaron Lisberg; Jesse M. Zaretsky; Tristan R. Grogan; Hira Rizvi; Daniel K. Wells; James Carroll; Amy Cummings; John Madrigal; Benjamin Jones; Jacklin Gukasyan; I. Peter Shintaku; Dennis Slamon; Steven Dubinett; Jonathan W. Goldman; David Elashoff; Matthew D. Hellmann; Antoni Ribas; Edward B. Garon
Author Choice
A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer
Thoudam Debraj Singh; Jaeyoung Song; Jina Kim; Jungwook Chin; Hyun Dong Ji; Jae-Eon Lee; Sang Bong Lee; Heeseok Yoon; Ji Hoon Yu; Sang Kyoon Kim; Ghil Suk Yoon; Hayoung Hwang; Ho Won Lee; Ji Min Oh; Sang-Woo Lee; Jaetae Lee; Hueng-Sik Choi; Soon-Young Na; Won-Il Choi; Young Joo Park; Young Shin Song; Young A. Kim; In-Kyu Lee; Sung Jin Cho; Yong Hyun Jeon
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Roland Seiler; Ewan A. Gibb; Natalie Q. Wang; Htoo Zarni Oo; Hung-Ming Lam; Kim E. van Kessel; Charlotte S. Voskuilen; Brian Winters; Nicholas Erho; Mandeep M. Takhar; James Douglas; Funda Vakar-Lopez; Simon J. Crabb; Bas W.G. van Rhijn; Elisabeth E. Fransen van de Putte; Ellen C. Zwarthoff; George N. Thalmann; Elai Davicioni; Joost L. Boormans; Marc Dall'Era; Michiel S. van der Heijden; Jonathan L. Wright; Peter C. Black
Author Choice
Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Stuart J. Smith; Betty M. Tyler; Toby Gould; Gareth J. Veal; Noah Gorelick; Jonathan Rowlinson; Riccardo Serra; Alison Ritchie; Phillip Berry; Annette Otto; John Choi; Nicolas Skuli; Maria Estevez-Cebrero; Kevin M. Shakesheff; Henry Brem; Richard G. Grundy; Ruman Rahman
Author Choice
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Milind D. Chalishazar; Sarah J. Wait; Fang Huang; Abbie S. Ireland; Anandaroop Mukhopadhyay; Younjee Lee; Sophia S. Schuman; Matthew R. Guthrie; Kristofer C. Berrett; Jeffery M. Vahrenkamp; Zeping Hu; Marek Kudla; Katarzyna Modzelewska; Guoying Wang; Nicholas T. Ingolia; Jason Gertz; David H. Lum; Sabina C. Cosulich; John S. Bomalaski; Ralph J. DeBerardinis; Trudy G. Oliver
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Ali Amin-Mansour; Suzanne George; Stefano Sioletic; Scott L. Carter; Mara Rosenberg; Amaro Taylor-Weiner; Chip Stewart; Aaron Chevalier; Sara Seepo; Adam Tracy; Gad Getz; Jason L. Hornick; Marisa R. Nucci; Bradley Quade; George D. Demetri; Chandrajit P. Raut; Levi A. Garraway; Eliezer M. Van Allen; Andrew J. Wagner
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Haesook T. Kim; Kwang Woo Ahn; Zhen-Huan Hu; Matthew S. Davids; Virginia O. Volpe; Joseph H. Antin; Mohamed L. Sorror; Mazyar Shadman; Oliver Press; Joseph Pidala; William Hogan; Robert Negrin; Steven Devine; Joseph Uberti; Edward Agura; Richard Nash; Jayesh Mehta; Joseph McGuirk; Stephen Forman; Amelia Langston; Sergio A. Giralt; Miguel-Angel Perales; Minoo Battiwalla; Gregory A. Hale; Robert Peter Gale; David I. Marks; Mehdi Hamadani; Sid Ganguly; Ulrike Bacher; Hillard Lazarus; Ran Reshef; Gerhard C. Hildebrandt; Yoshihiro Inamoto; Jean-Yves Cahn; Melhem Solh; Mohamed A. Kharfan-Dabaja; Nilanjan Ghosh; Ayman Saad; Mahmoud Aljurf; Harry C. Schouten; Brian T. Hill; Attaphol Pawarode; Tamila Kindwall-Keller; Nakhle Saba; Edward A. Copelan; Sunita Nathan; Amer Beitinjaneh; Bipin N. Savani; Jan Cerny; Michael R. Grunwald; Jean Yared; Baldeep M. Wirk; Taiga Nishihori; Saurabh Chhabra; Richard F. Olsson; Asad Bashey; Usama Gergis; Uday Popat; Ronald Sobecks; Edwin Alyea; Wael Saber; Jennifer R. Brown
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano; Elaine Yee Lin Chung; Eugenio Gaudio; Chiara Tarantelli; Luciano Cascione; Sara Napoli; Katti Jessen; Laura Carrassa; Valdemar Priebe; Giulio Sartori; Garrett Graham; Saravana P. Selvanathan; Andrea Cavalli; Andrea Rinaldi; Ivo Kwee; Monica Testoni; Davide Genini; B. Hilda Ye; Emanuele Zucca; Anastasios Stathis; Brian Lannutti; Jeffrey A. Toretsky; Francesco Bertoni
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.